<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04185168</url>
  </required_header>
  <id_info>
    <org_study_id>250</org_study_id>
    <nct_id>NCT04185168</nct_id>
  </id_info>
  <brief_title>Isoflavones and Peritoneal Dialysis</brief_title>
  <official_title>Effects of Isoflavones on Hypertension, Serum Concentrations of Fructoseamine and Advanced Glycated End Products in Peritoneal Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Nutrition and Food Technology Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Nutrition and Food Technology Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this double-blind randomized clinical trial is to determine the effects of
      isoflavones on serum concentrations of fructoseamine and advanced glycated end products in
      peritoneal dialysis patients. Forty-four patients from shafa clinic will randomly assign to
      either isoflavone or placebo group. The patients in isoflavone group will receive 100 mg soy
      isoflavone (as 2 capsules) daily for 8 weeks, while the placebo group will receive identical
      placebo. At the baseline and the end of the study,7 ml blood will be collected from each
      patient after a 12-14-hours fasting and serum concentrations of fructoseamine, carboxymethyl
      lysine, pentosidine, glucose will be measured. Furthermore, blood pressure measurements will
      be performed twice with a ten-minute interval between testing
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2019</start_date>
  <completion_date type="Actual">January 18, 2020</completion_date>
  <primary_completion_date type="Actual">January 18, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glucose</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum concentrations of glucose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fructoseamine</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum concentrations of fructoseamine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>carboxymethyl lysine</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum concentrations of carboxymethyl lysine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pentosidine</measure>
    <time_frame>8 weeks</time_frame>
    <description>Serum concentrations of pentosidine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Systolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diastolic blood pressure</measure>
    <time_frame>8 weeks</time_frame>
    <description>Diastolic blood pressure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Peritoneal Dialysis</condition>
  <arm_group>
    <arm_group_label>isoflavone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg soy isoflavone (as 2 tablets)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>soy isoflavone</intervention_name>
    <description>100 mg soy isoflavone (as 2 tablets)</description>
    <arm_group_label>isoflavone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>control</intervention_name>
    <description>2 tablets of placebo</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Continuous Ambulatory Peritoneal Dialysis for 6 months or more Body mass index below 35

        Exclusion Criteria:

        infections inflammatory diseases liver diseases Clinical diagnosis of cancer receiving
        glucocorticoid and anti-inflammatory drugs receiving isoflavone supplements Constant
        consumption of soy or foods containing soy in the diet
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Nutrition and Food Technology Research Institute</name>
      <address>
        <city>Tehran</city>
        <state>Iran (the Islamic Republic Of)</state>
        <zip>1981619573</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>December 1, 2019</study_first_submitted>
  <study_first_submitted_qc>December 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Nutrition and Food Technology Institute</investigator_affiliation>
    <investigator_full_name>zahra yari</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

